OBJECTIVES: The aim of this analysis is to estimate the cost-effectiveness of anidulafungin for the treatment of invasive candidiasis in Colombia. METHODS: We constructed a decision tree to determine the incremental cost-effectiveness ratio (ICER) of anidulafungin (200 mg on the first day, followed by 100 mg daily) compared to amphotericin B deoxycholate (0.7-1.0 mg daily); amphotericin B liposomal (5.0 mg/ kg daily); caspofungin (70 mg on the first day followed by 50 mg daily) and fluconazole (800 mg on the first day followed by 400 mg daily) for the treatment the patients with invasive candidiasis. The perspective is that of the Colombian health system including only direct costs. All currency units are in USD $ (1 USD$ = COP 1,971). We used a time horizon of life expectancy. A 5 % discount rate was used. The results were measured in quality-adjusted life year (QALY). The efficacy, safety and utility data were taken from the literature. Bayesian mixed treatment comparison method was applied for the comparison of treatments.  The costs of procedures were obtained of ISS tariff manual of 2001 and for drugs were used current price regulation and the SISMED database. Univariate and probabilistic sensitivity analyses were performed. RESULTS: The total expected costs per patient were: anidulafungin USD$ 4,685.61; amphotericin B deoxycholate USD$ 928.22; amphotericin B liposomal USD$ 25,569.12; caspofungin USD$ 3,368.48; fluconazole USD$ 628.39. The results for each alternative in terms of QALY were: anidulafungin 3.08; amphotericin B deoxycholate 2.26; amphotericin B liposomal 1.90; caspofungin 2.14; fluconazole 2.46. The ICER per QALY of anidulafungin compared to fluconazole was USD$ 6,521.38. Amphotericin B deoxycholate, amphotericin B liposomal and caspofungin were dominated alternatives. CONCLUSIONS: Assuming as threshold for Colombia GDP per capita USD$ 7,609.42 anidulafungin is a cost-effective alternative for the treatment of the patients with invasive candidiasis.